Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor.
Manipulation of angiogenesis may have a profound effect on female reproductive function, but this has not yet been demonstrated by direct experiment in species with ovulatory cycles similar to those in women. To investigate whether angiogenesis could be inhibited in the primate corpus luteum, and the consequences of such inhibition on luteal function, marmosets were treated with an antibody to vascular endothelial growth factor (VEGF). Treatment commenced at the time of ovulation and was continued for 3 days (early luteal group) or 10 days (midluteal group). Bromodeoxyuridine was used to label proliferating cells, being administered 1 h before collecting ovaries from control and treated animals in the early or midluteal phase. Ovarian sections were stained using an antibody to bromodeoxyuridine, and a proliferation index was obtained; endothelial cell quantification was performed using factor VIII as an endothelial cell marker. Intense proliferation in the early luteal phase was suppressed by anti-VEGF treatment. This resulted in blockade of development of the normally extensive capillary bed, as in the animals treated until the mid-luteal phase the numbers of endothelial cells were reduced. The hormone-producing cells remained largely unaltered in the posttreatment corpus luteum, although the presence of lipid accumulation, and small pockets of cells showing basophilia and nuclear condensation were observed. Significantly, luteal function, as judged by secretion of progesterone, was markedly compromised by the treatment, being reduced by 60% in comparison with controls. It is concluded that VEGF-mediated angiogenesis is an essential component of luteal function in primates and therefore has the potential to be regulated.
Fraser
H M
HM
Medical Research Council Reproductive Biology Unit, Center for Reproductive Biology, Edinburgh, United Kingdom. h.fraser@ed-rbu.mrc.ac.uk
Dickson
S E
SE
Lunn
S F
SF
Wulff
C
C
Morris
K D
KD
Carroll
V A
VA
Bicknell
R
R
D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D000963:Antimetabolites; D001973:Bromodeoxyuridine; D002144:Callithrix; D002455:Cell Division / Q000187:drug effects; D003338:Corpus Luteum / Q000098:blood supply* / Q000187:drug effects; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005260:Female; D007150:Immunohistochemistry; D008222:Lymphokines / Q000037:antagonists & inhibitors*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D012039:Regional Blood Flow / Q000187:drug effects; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D019138:Antibodies, Blocking; D000963:Antimetabolites; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D011374:Progesterone; D001973:Bromodeoxyuridine